Know Cancer

or
forgot password

Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex


Phase 2/Phase 3
4 Years
15 Years
Open (Enrolling)
Both
Tuberous Sclerosis Complex, TSC Related Cognitive Disability, TSC Related Autism, TSC Related Learning Problems

Thank you

Trial Information

Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex


Randomized double-blind placebo controlled intervention study in children with TSC between
age 4 and 15 years with an intelligence quotient (IQ) estimated <80 and/or special schooling
and/or autism spectrum disorder and/or learning disability requiring remedial teaching.

Patients are randomised to receive everolimus or placebo during a period of 12 months.


Inclusion Criteria:



- Children with a definite diagnosis of TSC between 4 and 15 years.

- With an IQ estimated <80 and/or special schooling and/or autism spectrum disorder
and/or learning disability requiring remedial teaching.

- Written informed consent by parents/care-takers, and the patient if he or she is 12
years or older and cognitively able to consent.

- In girls after menarche, appropriate contraception must be used or abstinence
practiced.

Exclusion Criteria:

- Hepatic dysfunction

- Surgery <6wk

- Current infection at time of inclusion

- Developmental age estimated below 3.5 years

- Intractable epilepsy with more than 1 seizure/week

- Inability to comply with the treatment protocol

- Additional diseases or disorders that may influence the endpoints, including:

- SEGA requiring treatment

- Uncontrolled diabetes mellitus

- Known impaired lung function

- Allergy for any of the components of the study medication

- Prior treatment with mTOR inhibitors

- HIV seropositivity

- Bleeding diathesis or oral anti-vitamin K medication

- Serum creatinine > 1.5 x ULN

- Uncontrolled hyperlipidemia (fasting serum cholesterol > 7.75 mmol/L, fasting serum
triglycerides > 2.5 x ULN)

- Use of investigational drug within 30 days prior to inclusion

- History of myocardial infarction, angina or stroke related to atherosclerosis, organ
transplantation, malignancy in the past 2 years

- Pregnancy or breastfeeding

- Children at risk for Hepatitis B (HB), unless hepatitis B serology is normal. Risk
groups are children who have lived in Asia, Africa, Central and South America,
Eastern Europe, Spain, Portugal, and Greece, children with known or suspected past or
current hepatitis B infection, current or prior IV illicit drug use, current or prior
dialysis, household contact with hepatitis B infected patient(s), current or prior
high-risk sexual activity, body piercing or tattoos, mother known to have hepatitis B
history. If vaccinated, presence of HBs Ab is normal.

- Known or suspected hepatitis C infection, unless hepatitis C serology is normal.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Cognitive ability measured by IQ

Outcome Description:

Assessed by Wechsler scales: Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III NL) and Wechsler Intelligence Scale for Children (WISC-III-NL)

Outcome Time Frame:

12 months

Safety Issue:

No

Principal Investigator

M.C.Y. de Wit, MD. PhD.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Erasmus Medical Center Rotterdam

Authority:

Netherlands: Medical Ethics Review Committee (METC)

Study ID:

NL38619.078.11

NCT ID:

NCT01730209

Start Date:

November 2012

Completion Date:

November 2016

Related Keywords:

  • Tuberous Sclerosis Complex
  • TSC Related Cognitive Disability
  • TSC Related Autism
  • TSC Related Learning Problems
  • Tuberous Sclerosis Complex
  • TSC
  • Autism
  • Learning problems
  • Everolimus
  • RAD001
  • Treatment
  • Cognition
  • Intellectual disability
  • Autistic Disorder
  • Sclerosis
  • Tuberous Sclerosis

Name

Location